| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/15/1999 | WO1999018116A1 Method for modulating gene expression |
| 04/15/1999 | WO1999018071A1 Azetidinone derivatives for the treatment of hcmv infections |
| 04/15/1999 | WO1999017803A1 Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug |
| 04/15/1999 | WO1999017798A1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/15/1999 | WO1999017797A1 Use of growth differenciation factor-9 (gdf-9) as a contraceptive |
| 04/15/1999 | WO1999017796A2 Modulation of lerk-2-mediated cell adhesion |
| 04/15/1999 | WO1999017795A1 RIBOSOME RECYCLING FACTOR (FRR) OF $i(STAPHYLOCOCCUS AUREUS) |
| 04/15/1999 | WO1999017794A1 UDP-N-ACETYLMURAMOYL-L-AIANINE:D-GLUTAMATE LIGASE (murD) OF STAPHYLOCOCCUS AUREUS |
| 04/15/1999 | WO1999017792A1 Methods and compositions for treating rheumatoid arthritis |
| 04/15/1999 | WO1999017791A1 Methods and compositions for reducing bacterial tolerance of disinfectants and organic solvents |
| 04/15/1999 | WO1999017784A1 Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
| 04/15/1999 | WO1999017779A1 Methods for treating psychosis associated with glucocorticoid related dysfunction |
| 04/15/1999 | WO1999017765A1 Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation |
| 04/15/1999 | WO1999017755A2 Medicaments |
| 04/15/1999 | WO1999017743A1 Dosage forms having improved release properties |
| 04/15/1999 | WO1999017742A2 Taste masked formulations |
| 04/15/1999 | WO1999017712A2 Tightening and/or reducing the size of body parts containing fat cells |
| 04/15/1999 | WO1999017709A2 Methods and compositions for treating rheumatoid arthritis |
| 04/15/1999 | WO1999017616A1 Structure-based rational design of compounds to inhibit papillomavirus infection |
| 04/15/1999 | WO1999017609A1 Nontoxic extract of larrea tridentata and method of making the same |
| 04/15/1999 | WO1999009054A3 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders |
| 04/15/1999 | WO1999008668A3 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 04/15/1999 | WO1999007324A3 Conjugates targeted to the interleukin-2 receptor |
| 04/15/1999 | WO1999005170A8 NOVEL ESTROGEN β RECEPTOR AND ISOFORMS |
| 04/15/1999 | WO1999004773A3 Method for inhibiting bone resorption |
| 04/15/1999 | WO1999002142A3 Novel composition comprising an ssri and a beta-blocker |
| 04/15/1999 | WO1999000422A9 Novel family of pheromone receptors |
| 04/15/1999 | WO1998052582A8 Non-myeloablative tolerogenic treatment |
| 04/15/1999 | WO1998029110A3 Formulation and method for treating neoplasms by inhalation |
| 04/15/1999 | CA2308126A1 Modulation of lerk-2-mediated cell adhesion |
| 04/15/1999 | CA2306452A1 Use of growth differentiation factor-9 (gdf-9) as a contraceptive |
| 04/15/1999 | CA2305751A1 Medicaments |
| 04/15/1999 | CA2305732A1 Methods for screening drugs to predict tardive dyskinesia |
| 04/15/1999 | CA2305726A1 Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
| 04/15/1999 | CA2305707A1 Mutants of yeast cdc24p, defective in binding of the g-protein beta subunit |
| 04/15/1999 | CA2305688A1 Methods and compositions for treating rheumatoid arthritis |
| 04/15/1999 | CA2305528A1 Methods and compositions for reducing bacterial tolerance of disinfectants and organic solvents |
| 04/15/1999 | CA2305045A1 Transgenic animals with knocked-in vec receptor genes and uses thereof |
| 04/15/1999 | CA2304630A1 Taste masked formulations |
| 04/15/1999 | CA2304354A1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/15/1999 | CA2273274A1 Dosage forms having improved release properties |
| 04/15/1999 | CA2273186A1 Structure-based rational design of compounds to inhibit papillomavirus infection |
| 04/14/1999 | EP0908519A1 Novel glucosaminidase from Staphylococcus aureus |
| 04/14/1999 | EP0908186A2 Method for treating pain |
| 04/14/1999 | EP0908178A1 Partial liquid breathing of fluorocarbons |
| 04/14/1999 | EP0907751A2 Dna, rna and a protein useful for detection of a mycobacterial infection |
| 04/14/1999 | EP0907742A2 Cyclic nucleotide phosphodiesterase |
| 04/14/1999 | EP0907738A1 Novel compounds |
| 04/14/1999 | EP0907729A1 HUMAN P2x4 RECEPTOR SPLICE-VARIANTS |
| 04/14/1999 | EP0907661A1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS |
| 04/14/1999 | EP0907644A1 Pharmaceutical preparation |
| 04/14/1999 | EP0907377A1 Novel compounds |
| 04/14/1999 | EP0907376A1 Novel compounds |
| 04/14/1999 | EP0907375A1 Novel compounds |
| 04/14/1999 | EP0907366A1 Combination therapy for treatment of erectile dysfunction |
| 04/14/1999 | EP0605501B1 Method and compositions for the treatment of cerebral palsy |
| 04/14/1999 | EP0584285B1 Treatment of schizophrenia by cholinesterase inhibitors |
| 04/14/1999 | CN1214052A Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 04/14/1999 | CN1214050A Human tumor necrosis factor delta and epsilon |
| 04/14/1999 | CN1213965A Use of antiarrhythmic compounds for reducing post-infarction morality |
| 04/13/1999 | CA2097196C Enteral preparation for cancer therapy |
| 04/13/1999 | CA2045553C Process for the preparation of vinyl ethers |
| 04/13/1999 | CA1340494C Induction of tolerance to a foreign antigen |
| 04/10/1999 | CA2249867A1 Osteoporosis compounds |
| 04/09/1999 | CA2246635A1 Novel glucosaminidase |
| 04/08/1999 | WO1999016888A2 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/08/1999 | WO1999016887A2 Compositions and methods for identifying pkb kinase inhibitors |
| 04/08/1999 | WO1999016875A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells |
| 04/08/1999 | WO1999016784A1 Ras-binding protein (pre1) |
| 04/08/1999 | WO1999016470A1 Oral preparation |
| 04/08/1999 | WO1999016460A2 Apolipoprotein e/growth factor complexes and methods of use |
| 04/08/1999 | WO1999016451A1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 04/08/1999 | WO1999016446A1 Pharmaceutical combination preparations containing endothelin antagonists and calcium antagonists |
| 04/08/1999 | WO1999016445A1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 04/08/1999 | WO1999016444A1 Endothelin antagonist and beta receptor blocking agent as combined preparations |
| 04/08/1999 | WO1999016427A1 Active agent transport systems |
| 04/08/1999 | WO1999016422A1 Stabilized preparations for use in metered dose inhalers |
| 04/08/1999 | WO1999016421A1 Stabilized bioactive preparations and methods of use |
| 04/08/1999 | WO1999016420A1 Stabilized preparations for use in nebulizers |
| 04/08/1999 | WO1999016419A1 Perforated microparticles and methods of use |
| 04/08/1999 | WO1999016407A2 Method and system for pain management |
| 04/08/1999 | WO1999016406A2 Therapeutic method |
| 04/08/1999 | WO1999004752A9 Methods for treating skin pigmentation |
| 04/08/1999 | WO1999003882A3 Human leukocyte calcium activated potassium channel polypeptide |
| 04/08/1999 | WO1999003489A3 Methods and compositions for regulating nuclear trafficking of proteins |
| 04/08/1999 | WO1998056919A9 Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 04/08/1999 | WO1998056913A9 Smad6 and uses thereof |
| 04/08/1999 | WO1998056910A9 DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE |
| 04/08/1999 | WO1998055638A9 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof |
| 04/08/1999 | WO1998055103A9 Anti-tumoral therapy agent |
| 04/08/1999 | CA2305686A1 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/08/1999 | CA2305179A1 Oral administration preparation |
| 04/08/1999 | CA2304951A1 Active agent transport systems |
| 04/08/1999 | CA2304720A1 Apolipoprotein e/growth factor complexes and methods of use |
| 04/08/1999 | CA2304484A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells |
| 04/08/1999 | CA2304209A1 Ras-binding protein (pre1) |
| 04/08/1999 | CA2298854A1 Compositions and methods for identifying pkb kinase inhibitors |
| 04/08/1999 | CA2245937A1 Novel histidine kinase |
| 04/08/1999 | CA2245924A1 A method of identifying agonists and antagonists for tumor necrosis related receptors tr1, tr3 and tr5 |
| 04/07/1999 | EP0906959A2 Aminopeptidase from Staphylococcus aureus |